Thyroid cancer dosimetry using clearance fitting.
Academic Article
Overview
abstract
UNLABELLED: Since 1962, Memorial Sloan Kettering Cancer Center has used an individually optimized dosimetry method for patients with thyroid carcinoma undergoing radioiodine therapy. This traditional dosimetry method involves a determination of the maximum tolerated activity or the activity that will deliver 2 Gy to the blood (A(max)), and the corresponding ablative lesion dose (D(lesion)). However, the traditional calculations of A(max) and D(lesion) were based on empirical assumptions. The objective of this work was to develop a dosimetry method that eliminates these assumptions by incorporating patient kinetics and that is not restricted to 131I as a tracer and therapeutic agent. METHODS: Patient kinetics were incorporated into the dosimetry algorithm by fitting parameters to patient clearance measurements. The radioiodines 123I, 124I, 125I and 131I were accommodated as tracers and therapeutic agents by incorporating their physical half lives and by precalculating photon-absorbed fractions for these radionuclides for several thousand patient geometries using Monte Carlo simulations. RESULTS: A(max) and D(lesion) have been calculated using the traditional and new method for a group of patients, and errors associated with each of the above assumptions were examined. Assuming that the initial blood activity is distributed instantaneously in 5 L was found to introduce an error in A(max) of up to 30%, whereas assuming physical decay beyond the last data point introduced an error of up to 50%. CONCLUSION: Individualized fitting of clearance data is a practical method to accurately account for inter-patient kinetics variations. The substitution of standard kinetics beyond measured data might lead to substantial errors in estimating A(max) and D(lesion). In addition, gamma camera images, rather than neck probe readings, should be used to determine lesion uptakes for thyroid cancer patients.
